www.gvt-journal.com

Table 2
Baseline parameters of all patients who were serum negative, PBMC positive at the EOT stage
Ser No.	Gender	Age yrs	ALT	cholest	HDL	LDL	T4	Treat	Quant x10⁶	Inflm	Fibr

1	M	35	NA	NA	NA	NA	NA	SIT	.56	3	3

2	M	55	18	NA	NA	NA	NA	SIT	1	3	2

3	F	34	71	90	40	102	178	SIT	.13	1	1

4	M	48	93	178	30	129	188	SIT	.006	3	0

5	F	32	78	199	38	96	179	SIT	.046	1	0

6	F	39	87	207	37	125	273	SIT	.001	1	0

7	F	49	76	160	42	98	180	SIT	1	NA	0

8	F	40	19	200	36	98	120	SIT	1	1	0

9	M	60	88	180	42	90	78	SIT	.0063	3	2

10	F	52	50	236	32	90	140	SIT	1	1	0

11	F	44	60	139	36	96	144	SIT	NA	1	0

12	F	37	96	190	36	107	220	SIT^r	1.81	1	1

13	F	36	19	139	40	75	140	SIT^r	.3	1	0

14	F	62	62	201	34	102	178	SIT^r	.04	1	0

15	F	49	46	NA	NA	NA	NA	SIT^r	.0127	NA	NA

16	F	51	112	198	32	86	120	SIT^nr	2.13	3	0

SIT^rrelapse to SIT SIT^nrnonresponder to SIT NA not available
Muazzam et al. Genetic Vaccines and Therapy 2011 9:14 doi:10.1186/1479-0556-9-14

Table 2